MyMD Pharmaceuticals, Inc. - Common Stock (NQ:MYMD)

1.820 UNCHANGED

Last Price Updated: 3:38 PM EDT, Jul 23, 2024 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about MyMD Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >

MyMD Pharmaceuticals Announces Issuance of New U.S. Patent Covering MYMD-1 in a Method of Treating Sarcopenia

January 05, 2022

From MyMD Pharmaceuticals, Inc.

Via Business Wire

MyMD Pharmaceuticals Investment Company Oravax Medical Signs Cooperation and Purchase Agreement for Initial Pre-Purchase of 10 Million Doses of Oral COVID-19 Vaccine to be Commercialized in Southeast Asia

December 29, 2021

From MyMD Pharmaceuticals, Inc.

Via Business Wire

MyMD Pharmaceuticals to Participate in Two Investor Conferences During December 2021

December 01, 2021

From MyMD Pharmaceuticals, Inc.

Via Business Wire

51 Biggest Movers From Yesterday ↗

December 28, 2021

Gainers Microbot Medical Inc. (NASDAQ: MBOT) shares climbed 65.1% to close at $8.95 on Monday after the company announced a strategic collaboration with Stryker Corporation to...

Via Benzinga

MyMD Pharmaceuticals Announces Issuance of U.S. Patent Covering Lead Drug Candidate MYMD-1 in a Method of Extending Lifespan

November 23, 2021

From MyMD Pharmaceuticals, Inc.

Via Business Wire

68 Biggest Movers From Wednesday ↗

November 26, 2021

Gainers AeroClean Technologies, Inc. (NASDAQ: AERC) shares gained 689.4% to settle at $78.94 on Wednesday after the company priced its IPO at $10 per share. Longeveron Inc. (...

Via Benzinga

Topics Initial Public Offering

MyMD Pharmaceuticals Investment Company Oravax Medical and Genomma Lab Announce Joint Venture to Develop and Commercialize Oral COVID-19 Vaccine in Mexico and Drive Business Development in Latin America

November 18, 2021

From MyMD Pharmaceuticals, Inc.

Via Business Wire

MyMD Pharmaceuticals Receives FDA IND Clearance to Begin Phase 2 Trial of MYMD-1 for Extending Healthy Lifespan

November 16, 2021

From MyMD Pharmaceuticals, Inc.

Via Business Wire

Super CBD To the Rescue? This Company Thinks So ↗

November 11, 2021

Photo by Kindel Media from Pexels The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial...

Via Benzinga

MyMD Pharmaceuticals President Chris Chapman, M.D. Named Medical Honoree of the Year by the Arthritis Foundation

October 26, 2021

From MyMD Pharmaceuticals, Inc.

Via Business Wire

MyMD Pharmaceuticals to Discuss its Novel Therapies for Aging and Related Diseases at the Dawson James Securities 6th Annual Small Cap Growth Conference on October 21

October 19, 2021

From MyMD Pharmaceuticals, Inc.

Via Business Wire

A First-of-its-Kind Drug Candidate Targeting the Root Causes of Aging Could Soon Dominate Estimated $600 Billion Aging Market ↗

October 18, 2021

Image on Unsplash The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga....

Via Benzinga

Cramer Likes Azek And SoFi, But Said Owning This Stock Could Be Dreadful ↗

October 08, 2021

On CNBC's "Mad Money Light...

Via Benzinga

Benzinga Announces The 8 'Rising Star' Companies Being Featured On Its Next 'All Access' Show ↗

October 06, 2021

Benzinga is thrilled to announce the guest lineup for our next All Access show, set to air Thursday, October 7 at 9:00 am ET. Thursday's Guest Lineup The theme...

Via Benzinga

MyMD Pharmaceuticals to Detail its Two Upcoming Phase 2 Trials at the Benzinga Rising Stars: Catalytic Small Cap Growth Conference on October 7

October 05, 2021

From MyMD Pharmaceuticals, Inc.

Via Business Wire

MyMD Pharmaceuticals Announces New Data Demonstrating 8,000 Times Higher Potency of Novel Synthetic Supera-CBD over Plant-Derived CBD

September 22, 2021

From MyMD Pharmaceuticals, Inc.

Via Business Wire

MyMD Pharmaceuticals Announces Fourth Quarter 2021 Initiation of Phase 2 Clinical Trial of MYMD-1 for Extending Healthy Lifespan

September 13, 2021

From MyMD Pharmaceuticals, Inc.

Via Business Wire

MyMD Pharmaceuticals to Present its Novel Therapeutic Platforms for Extending Healthy Lifespan at the H.C. Wainwright 23rd Annual Global Investment Conference September 13-15

September 09, 2021

From MyMD Pharmaceuticals, Inc.

Via Business Wire

MyMD Pharmaceuticals Announces Issuance of U.S. Patent for Use of Lead Candidate MYMD-1 for Treating Fibrosis and Asthma

August 24, 2021

From MyMD Pharmaceuticals, Inc.

Via Business Wire

MyMD Pharmaceuticals Announces Issuance of U.S. Patent for Synthetic Cannabinoid Compounds for Treating Neuroinflammatory and Neurodegenerative Diseases

August 10, 2021

From MyMD Pharmaceuticals, Inc.

Via Business Wire

85 Biggest Movers From Yesterday ↗

August 11, 2021

Gainers Fulcrum Therapeutics, Inc. (NASDAQ: FULC) jumped 125.3% to close at $18.77 on Tuesday after the company announced positive interim results from the Phase 1 trial with FTX...

Via Benzinga

MyMD Pharmaceuticals Subsidiary Oravax Medical Preparing to Commence Clinical Trials for Oral COVID-19 Vaccine

August 10, 2021

From MyMD Pharmaceuticals, Inc.

Via Business Wire

MyMD Pharma Stock Is Trading Higher As COVID-19 Candidate Effective In Suppressing Cytokine Storm ↗

August 05, 2021

MyMD Pharmaceuticals Inc (NASDAQ: MYMD) announces that a human cell research study of its lead compound MYMD-1 found the drug to effectively suppress the cytokine storm...

Via Benzinga

MyMD Pharmaceuticals’ Lead Compound MYMD-1 Shown to Suppress a Major Cause of Death in COVID-19 in Human Cell Study

August 05, 2021

From MyMD Pharmaceuticals, Inc.

Via Business Wire

MyMD Pharmaceuticals’ Lead Compound MYMD-1 Shows Commonality in Comparative Study with FDA-Approved Anti-Inflammatory and Anti-Autoimmune Drugs Used for Arthritis, Colitis and Dermatitis

July 27, 2021

From MyMD Pharmaceuticals, Inc.

Via Business Wire

MyMD Pharmaceuticals Announces New Data from Comparative Study on Lead Compound MYMD-1

July 07, 2021

From MyMD Pharmaceuticals, Inc.

Via Business Wire

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

June 16, 2021

Gainers Satsuma Pharmaceuticals (NASDAQ:STSA

Via Benzinga

MyMD Pharmaceuticals Set to Join Russell Microcap® Index

June 07, 2021

From MyMD Pharmaceuticals, Inc.

Via Business Wire

MyMD Pharmaceuticals Appoints David Rini, Professor at the Johns Hopkins School of Medicine, to Scientific Advisory Board

May 17, 2021

From MyMD Pharmaceuticals, Inc.

Via Business Wire

MyMD Pharmaceuticals Schedules Business Update Conference Call

May 12, 2021

From MyMD Pharmaceuticals, Inc.

Via Business Wire

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.